Clinical Trial

AGILE (Early Phase Platform Trial for COVID-19)

Study acronym: AGILE
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The AGILE platform master protocol allows incorporation of a range of identified and yet-to-be-identified candidates as potential treatments for adults with COVID-19 into the trial. Candidates will be added into the trial via candidate-specific trial (CST) protocols of this master protocol as appendices. Having one master protocol ensures different candidates are evaluated in the same consistent manor and opening up new trials for new candidates is more efficient. Inclusion of new candidates will be based on pre-clinical data, evidence in the clinical setting and GMP capabilities.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-07-31 -> 2027-03-31 2026-06-02
minor Completion pushed: 2026-07-31 -> 2027-03-31 2026-06-02
Trial Details
NCT Number NCT04746183
Lead Sponsor University of Liverpool
Collaborators: Liverpool School of Tropical Medicine, Royal Liverpool University Hospital, University of Cambridge
Conditions Covid19
Enrollment 600 participants
Start Date 2020-07-03
Primary Completion 2027-03-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-01